“Characterization of ORKA-001, a Novel Extended Half-life Monoclonal Antibody Targeting IL-23 for the Treatment of Psoriasis” (2025) SKIN The Journal of Cutaneous Medicine, 9(2), p. s527. doi:10.25251/skin.10.supp.527.